The Basic Advocacy Training SessionThe training for certification includes a variety of topics to give advocates a well-grounded understanding of MAT, research, regulations and laws that protect MAT patients and programs.
|
The Basic Advocacy Training SessionThe training for certification includes a variety of topics to give advocates a well-grounded understanding of MAT, research, regulations and laws that protect MAT patients and programs.
|
Methadone Advocacy The National Alliance of Methadone Advocates (NAMA) holds the view that every individual who believes in methadone treatment is at least a potential Certified Methadone Advocate (CMA). We encourage all supporters of methadone treatment, patient and non-patient, to become Certified Methadone Advocates so that all energies directed toward the advancement of methadone treatment…
Please enable cookies. You are unable to access this email address Methadone.org The website from which you got to this page is protected by Cloudflare. Email addresses on that page have been hidden in order to keep them from being accessed by malicious bots. You must enable Javascript in your browser in order to decode…
Policy Statement 1 Methadone Medical Maintenance April 1994 Download File (pdf format) Policy Statement 2 The Policy of Blind Dosing and Patient Dignity April 18, 1994 Download File (pdf format) Policy Statement 3 Discharge From Treatment for Drug Use May 1994 Download File (pdf format) Policy Statement 4 Patient vs Client May 1994 Download File (pdf format) Policy…
Recertify for Your Medication Assisted Treatment Advocate (CMA) About Recertification We have had many persons who are certified contact us about recertification. Previously the only way to recertify was to take the training again. There have been some CMAs who saw their certification as so valuable that they have taken the training again. Steps to…
Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations (i) Unsupervised or take-home use. To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements. (1) Any patient…